Correlation between TAP detection and common digestive tract precancerous lesions

Area of Science:

• Gastroenterology
• Oncology
• Biochemistry

Background:

• Digestive tract cancers, including colon adenocarcinoma, pose significant health challenges.
• Early detection of precancerous lesions is crucial for effective treatment and improved patient outcomes.
• Tumor abnormal protein (TAP), a sugar-chain glycoprotein, is implicated in cellular processes relevant to cancer development.

Purpose of the Study:

• To investigate the clinical significance of abnormal sugar-chain glycoprotein tumor abnormal protein (TAP) in screening for precancerous colon adenocarcinoma lesions.
• To evaluate the correlation between TAP expression and different stages of digestive tract abnormalities, from inflammation to cancer.
• To determine the predictive value of TAP in assessing tumor incidence and recurrence.

Main Methods:

• A cohort study involving 50 patients each with colitis, colon polyps, and colon adenocarcinoma.
• Detection of TAP expression in fresh fingertip blood samples using condensation staining.
• Statistical analysis to compare TAP-positive rates across groups and correlate with clinical outcomes.

Main Results:

• TAP-positive expression rates were 6% in colitis, 76% in colon polyps, and 92% in colon adenocarcinoma patients (P<0.05).
• TAP-positive expression showed a significant increasing trend across these groups.
• TAP-positive patients exhibited higher tumor incidence (colitis/polyps) and recurrence rates (adenocarcinoma) (P<0.05).

Conclusions:

• Abnormal sugar-chain glycoprotein tumor abnormal protein (TAP) expression is significantly elevated in precancerous colon lesions.
• TAP is correlated with the progression from intestinal inflammation to colon polyps and canceration.
• TAP serves as a potential biomarker for screening digestive tract precancerous lesions and predicting patient outcomes.